Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: Combined results from the PRIMO-CABG I and II trials (Q85110492)
Jump to navigation
Jump to search
scientific article published on September 28, 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: Combined results from the PRIMO-CABG I and II trials |
scientific article published on September 28, 2010 |
Statements
Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials (English)
Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: Combined results from the PRIMO-CABG I and II trials (English)
Michel Carrier
PRIMO-CABG II Investigators
Peter K. Smith
Stanton K. Shernan
John C. Chen
Edward D. Verrier
Peter X. Adams
Thomas G. Todaro
Lawrence H. Muhlbaier
28 September 2010